{"count": 89, "results": [{"_id": "33710319", "pmid": 33710319, "pmcid": "PMC8645269", "title": "beta-blocker prescription is associated with lower cumulative risk of knee osteoarthritis and knee pain consultations in primary care: a propensity score-matched cohort study", "journal": "Rheumatology (Oxford)", "authors": ["Nakafero G", "Grainge MJ", "Valdes AM", "Townsend N", "D Mallen C", "Zhang W", "Doherty M", "Mamas M", "Abhishek A"], "date": "2021-12-01T00:00:00Z", "doi": "10.1093/rheumatology/keab234", "meta_date_publication": "2021 Dec 1", "meta_volume": "60", "meta_issue": "12", "meta_pages": "5686-5696", "score": 50259.19, "text_hl": "It reduces both intraoperative [standard mean difference (SMD) (95% CI) -1.60 (-2.25, -0.96)] and post-anaesthesia opioid consumption [SMD (95% CI) -1.21 (-1.66, -0.77)]. @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@Atenolol@@@ is used for the treatment of @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular conditions@@@ such as @DISEASE_Angina_Pectoris @DISEASE_MESH:D000787 @@@angina@@@, @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ and @DISEASE_Tachycardia_Supraventricular @DISEASE_MESH:D013617 @@@supraventricular tachycardia@@@, and our findings suggest that it might be suitable for the treatment of @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular co-morbidities@@@ in symptomatic @DISEASE_Osteoarthritis @DISEASE_MESH:D010003 @@@OA@@@ @SPECIES_9606 @@@patients@@@. ", "citations": {"NLM": "Nakafero G, Grainge MJ, Valdes AM, Townsend N, D Mallen C, Zhang W, Doherty M, Mamas M, Abhishek A. beta-blocker prescription is associated with lower cumulative risk of knee osteoarthritis and knee pain consultations in primary care: a propensity score-matched cohort study Rheumatology (Oxford). 2021 Dec 1;60(12):5686-5696. PMID: 33710319", "BibTeX": "@article{33710319, title={beta-blocker prescription is associated with lower cumulative risk of knee osteoarthritis and knee pain consultations in primary care: a propensity score-matched cohort study}, author={Nakafero G and Grainge MJ and Valdes AM and Townsend N and D Mallen C and Zhang W and Doherty M and Mamas M and Abhishek A}, journal={Rheumatology (Oxford)}, volume={60}, number={12}, pages={5686-5696}}"}}, {"_id": "35482263", "pmid": 35482263, "title": "Investigating the biological degradation of the drug beta-blocker atenolol from wastewater using the SBR.", "journal": "Biodegradation", "authors": ["Rezaei R", "Aghapour AA", "Khorsandi H"], "date": "2022-06-01T00:00:00Z", "doi": "10.1007/s10532-022-09979-w", "meta_date_publication": "2022 Jun", "meta_volume": "33", "meta_issue": "3", "meta_pages": "267-281", "score": 50257.81, "text_hl": "Drug compounds are one of the main contributors to the entry of micro-pollutants into the environment, known as a constant threat to environmental stability. @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@Atenolol@@@ is a type of beta-blocker extensively used to cure @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular disorders@@@. ", "citations": {"NLM": "Rezaei R, Aghapour AA, Khorsandi H. Investigating the biological degradation of the drug beta-blocker atenolol from wastewater using the SBR. Biodegradation. 2022 Jun;33(3):267-281. PMID: 35482263", "BibTeX": "@article{35482263, title={Investigating the biological degradation of the drug beta-blocker atenolol from wastewater using the SBR.}, author={Rezaei R and Aghapour AA and Khorsandi H}, journal={Biodegradation}, volume={33}, number={3}, pages={267-281}}"}}, {"_id": "31640931", "pmid": 31640931, "title": "Atenolol thiourea hybrid as potent urease inhibitors: Design, biology-oriented drug synthesis, inhibitory activity screening, and molecular docking studies.", "journal": "Bioorg Chem", "authors": ["Wahid S", "Jahangir S", "Versiani MA", "Khan KM", "Salar U", "Ashraf M", "Farzand U", "Wadood A", "Kanwal", "Ashfaq-Ur-Rehaman", "Arshia", "Taha M", "Perveen S"], "date": "2020-01-01T00:00:00Z", "doi": "10.1016/j.bioorg.2019.103359", "meta_date_publication": "2020 Jan", "meta_volume": "94", "meta_issue": "", "meta_pages": "103359", "score": 50249.473, "text_hl": "Current research deals with the biology-oriented drug synthesis (BIODS) of twenty-three new @CHEMICAL_Thiourea @CHEMICAL_MESH:D013890 @@@thiourea@@@ analogs of pharmacologically important drug @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ which is a well-known medicine to treat @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ as well as @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular diseases@@@ (@<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@CVDs@@@). ", "citations": {"NLM": "Wahid S, Jahangir S, Versiani MA, Khan KM, Salar U, Ashraf M, Farzand U, Wadood A, Kanwal, Ashfaq-Ur-Rehaman, Arshia, Taha M, Perveen S. Atenolol thiourea hybrid as potent urease inhibitors: Design, biology-oriented drug synthesis, inhibitory activity screening, and molecular docking studies. Bioorg Chem. 2020 Jan;94():103359. PMID: 31640931", "BibTeX": "@article{31640931, title={Atenolol thiourea hybrid as potent urease inhibitors: Design, biology-oriented drug synthesis, inhibitory activity screening, and molecular docking studies.}, author={Wahid S and Jahangir S and Versiani MA and Khan KM and Salar U and Ashraf M and Farzand U and Wadood A and Kanwal and Ashfaq-Ur-Rehaman and Arshia and Taha M and Perveen S}, journal={Bioorg Chem}, volume={94}, pages={103359}}"}}, {"_id": "33186492", "pmid": 33186492, "title": "Polypill with or without Aspirin in Persons without Cardiovascular Disease.", "journal": "N Engl J Med", "authors": ["Yusuf S", "Joseph P", "Dans A", "Gao P", "Teo K", "Xavier D", "López-Jaramillo P", "Yusoff K", "Santoso A", "Gamra H", "Talukder S", "Christou C", "Girish P", "Yeates K", "Xavier F", "Dagenais G", "Rocha C", "McCready T", "Tyrwhitt J", "Bosch J", "Pais P", "International Polycap Study 3 Investigators"], "date": "2021-01-21T00:00:00Z", "doi": "10.1056/NEJMoa2028220", "meta_date_publication": "2021 Jan 21", "meta_volume": "384", "meta_issue": "3", "meta_pages": "216-228", "score": 50248.04, "text_hl": "METHODS: Using a 2-by-2-by-2 factorial design, we randomly assigned participants without @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular disease@@@ who had an elevated INTERHEART Risk Score to receive a polypill (containing 40 mg of @CHEMICAL_Simvastatin @CHEMICAL_MESH:D019821 @@@simvastatin@@@, 100 mg of @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@, 25 mg of @CHEMICAL_Hydrochlorothiazide @CHEMICAL_MESH:D006852 @@@hydrochlorothiazide@@@, and 10 mg of @CHEMICAL_Ramipril @CHEMICAL_MESH:D017257 @@@ramipril@@@) or placebo daily, @CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@aspirin@@@ (75 mg) or placebo daily, and @CHEMICAL_Vitamin_D @CHEMICAL_MESH:D014807 @@@vitamin D@@@ or placebo monthly. ", "citations": {"NLM": "Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, López-Jaramillo P, Yusoff K, Santoso A, Gamra H, Talukder S, Christou C, Girish P, Yeates K, Xavier F, Dagenais G, Rocha C, McCready T, Tyrwhitt J, Bosch J, Pais P, International Polycap Study 3 Investigators. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med. 2021 Jan 21;384(3):216-228. PMID: 33186492", "BibTeX": "@article{33186492, title={Polypill with or without Aspirin in Persons without Cardiovascular Disease.}, author={Yusuf S and Joseph P and Dans A and Gao P and Teo K and Xavier D and López-Jaramillo P and Yusoff K and Santoso A and Gamra H and Talukder S and Christou C and Girish P and Yeates K and Xavier F and Dagenais G and Rocha C and McCready T and Tyrwhitt J and Bosch J and Pais P and International Polycap Study 3 Investigators}, journal={N Engl J Med}, volume={384}, number={3}, pages={216-228}}"}}, {"_id": "32403073", "pmid": 32403073, "title": "Analysis of quinary therapy targeting multiple cardiovascular diseases using UV spectrophotometry and chemometric tools.", "journal": "Spectrochim Acta A Mol Biomol Spectrosc", "authors": ["Elsonbaty A", "Serag A", "Abdulwahab S", "Hassan WS", "Eissa MS"], "date": "2020-09-05T00:00:00Z", "doi": "10.1016/j.saa.2020.118415", "meta_date_publication": "2020 Sep 5", "meta_volume": "238", "meta_issue": "", "meta_pages": "118415", "score": 50247.71, "text_hl": "Analysis of quinary therapy targeting multiple @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular diseases@@@ using UV spectrophotometry and chemometric tools.", "citations": {"NLM": "Elsonbaty A, Serag A, Abdulwahab S, Hassan WS, Eissa MS. Analysis of quinary therapy targeting multiple cardiovascular diseases using UV spectrophotometry and chemometric tools. Spectrochim Acta A Mol Biomol Spectrosc. 2020 Sep 5;238():118415. PMID: 32403073", "BibTeX": "@article{32403073, title={Analysis of quinary therapy targeting multiple cardiovascular diseases using UV spectrophotometry and chemometric tools.}, author={Elsonbaty A and Serag A and Abdulwahab S and Hassan WS and Eissa MS}, journal={Spectrochim Acta A Mol Biomol Spectrosc}, volume={238}, pages={118415}}"}}, {"_id": "36962886", "pmid": 36962886, "pmcid": "PMC10021517", "title": "The availability of essential medicines for cardiovascular diseases at healthcare facilities in low- and middle-income countries: The case of Bangladesh", "journal": "PLOS Glob Public Health", "authors": ["Hakim S", "Chowdhury MAB", "Haque MA", "Ahmed NU", "Paul GK", "Uddin MJ"], "date": "2022-11-28T00:00:00Z", "doi": "10.1371/journal.pgph.0001154", "meta_date_publication": "2022", "meta_volume": "2", "meta_issue": "11", "meta_pages": "e0001154", "score": 50245.93, "text_hl": "The outcome variable \"@<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@EM-CVD@@@ availability\" was calculated as a counting score of the following tracer medicines: angiotensin-converting enzyme (ACE) inhibitors (@CHEMICAL_Enalapril @CHEMICAL_MESH:D004656 @@@enalapril@@@), @CHEMICAL_Thiazides @CHEMICAL_MESH:D049971 @@@thiazide@@@, beta-blockers (@<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@), calcium channel blockers (@CHEMICAL_Amlodipine @CHEMICAL_MESH:D017311 @@@amlodipine@@@ and @CHEMICAL_Nifedipine @CHEMICAL_MESH:D009543 @@@nifedipine@@@), @CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@aspirin@@@, and @CHEMICAL_Simvastatin @CHEMICAL_MESH:D019821 @@@simvastatin@@@/@CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin@@@. ", "citations": {"NLM": "Hakim S, Chowdhury MAB, Haque MA, Ahmed NU, Paul GK, Uddin MJ. The availability of essential medicines for cardiovascular diseases at healthcare facilities in low- and middle-income countries: The case of Bangladesh PLOS Glob Public Health. 2022;2(11):e0001154. PMID: 36962886", "BibTeX": "@article{36962886, title={The availability of essential medicines for cardiovascular diseases at healthcare facilities in low- and middle-income countries: The case of Bangladesh}, author={Hakim S and Chowdhury MAB and Haque MA and Ahmed NU and Paul GK and Uddin MJ}, journal={PLOS Glob Public Health}, volume={2}, number={11}, pages={e0001154}}"}}, {"_id": "36662714", "pmid": 36662714, "pmcid": "PMC9858374", "title": "Utilizing quantitative dried blood spot analysis to objectively assess adherence to cardiovascular pharmacotherapy among patients at Kenyatta National Hospital, Nairobi, Kenya", "journal": "PLoS One", "authors": ["Wata D", "Ogwu J", "Dunford L", "Lawson G", "Tanna S"], "date": "2023-01-20T00:00:00Z", "doi": "10.1371/journal.pone.0280137", "meta_date_publication": "2023", "meta_volume": "18", "meta_issue": "1", "meta_pages": "e0280137", "score": 50245.37, "text_hl": "The target @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@CVD@@@ medications were @CHEMICAL_Amlodipine @CHEMICAL_MESH:D017311 @@@amlodipine@@@, @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@, @CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin@@@, @CHEMICAL_Losartan @CHEMICAL_MESH:D019808 @@@losartan@@@ and @CHEMICAL_Valsartan @CHEMICAL_MESH:D000068756 @@@valsartan@@@. ", "citations": {"NLM": "Wata D, Ogwu J, Dunford L, Lawson G, Tanna S. Utilizing quantitative dried blood spot analysis to objectively assess adherence to cardiovascular pharmacotherapy among patients at Kenyatta National Hospital, Nairobi, Kenya PLoS One. 2023;18(1):e0280137. PMID: 36662714", "BibTeX": "@article{36662714, title={Utilizing quantitative dried blood spot analysis to objectively assess adherence to cardiovascular pharmacotherapy among patients at Kenyatta National Hospital, Nairobi, Kenya}, author={Wata D and Ogwu J and Dunford L and Lawson G and Tanna S}, journal={PLoS One}, volume={18}, number={1}, pages={e0280137}}"}}, {"_id": "33708114", "pmid": 33708114, "pmcid": "PMC7941209", "title": "Access to Essential Cardiovascular Medicines in Pakistan: A National Survey on the Availability, Price, and Affordability, Using WHO/HAI Methodology", "journal": "Front Pharmacol", "authors": ["Saeed A", "Saeed F", "Saeed H", "Saleem Z", "Yang C", "Chang J", "Jiang M", "Zhao M", "Saqlain M", "Ji W", "Aziz MM", "Lambojon K", "Gillani AH", "Hayat K", "Gul S", "Fang Y", "Babar ZU"], "date": "2021-01-25T00:00:00Z", "doi": "10.3389/fphar.2020.595008", "meta_date_publication": "2020", "meta_volume": "11", "meta_issue": "", "meta_pages": "595008", "score": 50243.234, "text_hl": "In international comparison with countries such as Sudan, Lebanon, Egypt, India, Afghanistan, and China, the affordability of standard treatment with selected @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@CVD@@@ medicines (@<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@, @CHEMICAL_Amlodipine @CHEMICAL_MESH:D017311 @@@amlodipine@@@, @CHEMICAL_Captopril @CHEMICAL_MESH:D002216 @@@captopril@@@, and @CHEMICAL_Simvastatin @CHEMICAL_MESH:D019821 @@@simvastatin@@@) in Pakistan was found to be low. ", "citations": {"NLM": "Saeed A, Saeed F, Saeed H, Saleem Z, Yang C, Chang J, Jiang M, Zhao M, Saqlain M, Ji W, Aziz MM, Lambojon K, Gillani AH, Hayat K, Gul S, Fang Y, Babar ZU. Access to Essential Cardiovascular Medicines in Pakistan: A National Survey on the Availability, Price, and Affordability, Using WHO/HAI Methodology Front Pharmacol. 2020;11():595008. PMID: 33708114", "BibTeX": "@article{33708114, title={Access to Essential Cardiovascular Medicines in Pakistan: A National Survey on the Availability, Price, and Affordability, Using WHO/HAI Methodology}, author={Saeed A and Saeed F and Saeed H and Saleem Z and Yang C and Chang J and Jiang M and Zhao M and Saqlain M and Ji W and Aziz MM and Lambojon K and Gillani AH and Hayat K and Gul S and Fang Y and Babar ZU}, journal={Front Pharmacol}, volume={11}, pages={595008}}"}}, {"_id": "36029011", "pmid": 36029011, "title": "Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified.", "journal": "Blood Press", "authors": ["Esler M", "Kjeldsen SE", "Pathak A", "Grassi G", "Kreutz R", "Mancia G"], "date": "2022-12-01T00:00:00Z", "doi": "10.1080/08037051.2022.2110858", "meta_date_publication": "2022 Dec", "meta_volume": "31", "meta_issue": "1", "meta_pages": "210-224", "score": 50233.668, "text_hl": "Beta-blockers have solid documentation in preventing @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular complications@@@ in the treatment of @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@; @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@, @CHEMICAL_Metoprolol @CHEMICAL_MESH:D008790 @@@metoprolol@@@, @CHEMICAL_Oxprenolol @CHEMICAL_MESH:D010096 @@@oxprenolol@@@ and @CHEMICAL_Propranolol @CHEMICAL_MESH:D011433 @@@propranolol@@@ demonstrate proven cardiovascular prevention in @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ mega-trials. ", "citations": {"NLM": "Esler M, Kjeldsen SE, Pathak A, Grassi G, Kreutz R, Mancia G. Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified. Blood Press. 2022 Dec;31(1):210-224. PMID: 36029011", "BibTeX": "@article{36029011, title={Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified.}, author={Esler M and Kjeldsen SE and Pathak A and Grassi G and Kreutz R and Mancia G}, journal={Blood Press}, volume={31}, number={1}, pages={210-224}}"}}, {"_id": "32310006", "pmid": 32310006, "title": "Treatment for beta-blocker poisoning: a systematic review.", "journal": "Clin Toxicol (Phila)", "authors": ["Rotella JA", "Greene SL", "Koutsogiannis Z", "Graudins A", "Hung Leang Y", "Kuan K", "Baxter H", "Bourke E", "Wong A"], "date": "2020-10-01T00:00:00Z", "doi": "10.1080/15563650.2020.1752918", "meta_date_publication": "2020 Oct", "meta_volume": "58", "meta_issue": "10", "meta_pages": "943-983", "score": 50216.492, "text_hl": "However, it is reasonable to have a graduated response to @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular instability@@@ beginning with intravenous fluids, commencement of a single or a combination of @CHEMICAL_Catecholamines @CHEMICAL_MESH:D002395 @@@catecholamine@@@ inotropes and vasopressors depending upon the type of haemodynamic compromise (@DISEASE_Bradycardia @DISEASE_MESH:D001919 @@@bradycardia@@@, @DISEASE_Ventricular_Dysfunction_Left @DISEASE_MESH:D018487 @@@left ventricular dysfunction@@@, vasodilation). ", "citations": {"NLM": "Rotella JA, Greene SL, Koutsogiannis Z, Graudins A, Hung Leang Y, Kuan K, Baxter H, Bourke E, Wong A. Treatment for beta-blocker poisoning: a systematic review. Clin Toxicol (Phila). 2020 Oct;58(10):943-983. PMID: 32310006", "BibTeX": "@article{32310006, title={Treatment for beta-blocker poisoning: a systematic review.}, author={Rotella JA and Greene SL and Koutsogiannis Z and Graudins A and Hung Leang Y and Kuan K and Baxter H and Bourke E and Wong A}, journal={Clin Toxicol (Phila)}, volume={58}, number={10}, pages={943-983}}"}}]}